Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single and repeated dose study of STN1013600 ophthalmic solution in healthy adult males
jRCT2031210614Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ursodeoxycholic acid in presbyopia, sponsored by Santen Pharmaceutical. Primary endpoint: Safety: Adverse events and adverse drug reactions. Started Feb 2022; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
presbyopia
Beyond the preview
Go deeper on jRCT2031210614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210614.